Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg IFNα-2b Add-on to NAs in HBV-Related Compensatory Cirrhosis
NCT03969017Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in hepatitis B (HBV), Liver cirrhosis (LC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis B (HBV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03969017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969017.